Drug-eluting stents—what should be improved?

References

• Horlitz M, Sigwart U, Niebauer J. Fighting restenosis after coronary angioplasty: contemporary and future treatment options. Int J Cardiol. 2002; 83: 199–205
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331: 489–95
   PubMed Web of Science ®Google Scholar
• Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994; 331: 496–501
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773–80
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315–23
   PubMed Web of Science ®Google Scholar
• Shaknovich A. Complications of coronary stenting. Coron Artery Dis. 1994; 5: 583–9
   PubMed Web of Science ®Google Scholar
• McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004; 364: 1519–21
   PubMed Web of Science ®Google Scholar
• Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007; 356: 998–1008
   PubMed Web of Science ®Google Scholar
• Camenzind, E, Steg, PG, Wijns, W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115:1440–55; discussion 1455.
   PubMed Web of Science ®Google Scholar
• Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007; 115: 1051–8
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293: 2126–30
   PubMed Web of Science ®Google Scholar
• Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005; 45: 2088-9-2
   Google Scholar
• Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007; 356: 989–97
   PubMed Web of Science ®Google Scholar
• Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007; 356: 1020–9
   PubMed Web of Science ®Google Scholar
• Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995; 76: 412–7
   PubMed Web of Science ®Google Scholar
• Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996; 98: 2277–83
   PubMed Web of Science ®Google Scholar
• Butzal M, Loges S, Schweizer M, Fischer U, Gehling UM, Hossfeld DK, et al. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res. 2004; 300: 65–71
   Google Scholar
• Inoue T, Sata M, Hikichi Y, Sohma R, Fukuda D, Uchida T, et al. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation. 2007; 115: 553–61
   PubMed Web of Science ®Google Scholar
• Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Luscher TF, et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation. 2005; 112: 2002–11
   PubMed Web of Science ®Google Scholar
• Stahli BE, Camici GG, Steffel J, Akhmedov A, Shojaati K, Graber M, et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res. 2006; 99: 149–55
   PubMed Web of Science ®Google Scholar
• Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006; 48: 193–202
   PubMed Web of Science ®Google Scholar
• Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006; 47: 175–81
   PubMed Web of Science ®Google Scholar
• Hara H, Nakamura M, Palmaz JC, Schwartz RS. Role of stent design and coatings on restenosis and thrombosis. Adv Drug Deliv Rev. 2006; 58: 377–86
   PubMed Web of Science ®Google Scholar
• Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006; 114: 798–806
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006; 48: 2440–7
   PubMed Web of Science ®Google Scholar
• van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR, Jr, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996; 94: 1690–7
   PubMed Web of Science ®Google Scholar
• Costa RA, Lansky AJ, Abizaid A, Mueller R, Tsuchiya Y, Mori K, et al. Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol. 2006; 98: 443–6
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y, et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol. 2006; 98: 464–9
   PubMed Web of Science ®Google Scholar
• Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation. 2006; 113: 273–9
   PubMed Web of Science ®Google Scholar
• Wieneke H, Dirsch O, Sawitowski T, Gu YL, Brauer H, Dahmen U, et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc Interv. 2003; 60: 399–407
   PubMed Web of Science ®Google Scholar
• Grube E, Buellesfeld L. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents. Herz. 2004; 29: 162–6
   PubMed Web of Science ®Google Scholar
• Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation. 2004; 109: 487–93
   PubMed Web of Science ®Google Scholar
• Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation. 2004; 109: 1948–54
   PubMed Web of Science ®Google Scholar
• Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent Trial Conclusions. Available at: http://www.jnj.com/news/jnj_news/20070507_080915.htm, , (accessed 6 July 2007).
   Google Scholar
• Han YL, Wang SL, Jing QM, Yu HB, Wang B, Ma YY, et al. Midterm outcomes of prospective, randomized, single-center study of the Janus tacrolimus-eluting stent for treatment of native coronary artery lesions. Chin Med J (Engl) 2007; 120: 552–6
   Google Scholar
• Windecker S, Billinger M, Hess OM. Stent coating with titanium-nitric-oxide for prevention of restenosis. EuroIntervention. 2006; 2: 146–8
   PubMedGoogle Scholar
• Windecker S, Simon R, Lins M, Klauss V, Eberli FR, Roffi M, et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation. 2005; 111: 2617–22
   PubMed Web of Science ®Google Scholar
• Karjalainen PP, Ylitalo A, Airaksinen JK. Titanium and nitride oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population. J Invasive Cardiol. 2006; 18: 462–8
   PubMedGoogle Scholar
• Urao N, Okigaki M, Yamada H, Aadachi Y, Matsuno K, Matsui A, et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res. 2006; 98: 1405–13
   PubMed Web of Science ®Google Scholar
• Griese DP, Ehsan A, Melo LG, Kong D, Zhang L, Mann MJ, et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation. 2003; 108: 2710–5
   PubMed Web of Science ®Google Scholar
• Chen TG, Chen JZ, Wang XX. Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Prolif. 2006; 39: 117–25
   Google Scholar
• Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol. 2005; 45: 1574–9
   PubMed Web of Science ®Google Scholar
• Blindt R, Vogt F, Astafieva I, Fach C, Hristov M, Krott N, et al. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J Am Coll Cardiol. 2006; 47: 1786–95
   PubMed Web of Science ®Google Scholar
• Adriaenssens T, Mehilli J, Wessely R, Ndrepepa G, Seyfarth M, Wieczorek A, et al. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J Am Coll Cardiol. 2007; 49: 1265–71
   PubMed Web of Science ®Google Scholar
• Liu, X, Huang, Y, Hanet, C, Vandormael, M, Legrand, V, Dens, J, , et al. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv. 2003;60:172–8; discussion 179.
   PubMed Web of Science ®Google Scholar
• Ribichini F, Tomai F, Paloscia L, Di Sciascio G, Carosio G, Romano M, et al. Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry. Heart. 2007; 93: 598–600
   Google Scholar
• Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res. 2001; 49: 281–7
   PubMed Web of Science ®Google Scholar
• Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation. 2002; 105: 1756–9
   PubMed Web of Science ®Google Scholar
• Vaina S, Serruys PW. Progressive stent technologies: new approaches for the treatment of cardiovascular diseases. Expert Opin Drug Deliv. 2006; 3: 783–97
   PubMedGoogle Scholar
• Abizaid A, Albertal M, Ormiston J, Londero H, Ruygrok P, Seixas AC, et al. IMPACT Trial: angiographic and intravascular ultrasound observations of the first human experience with mycophenolic acid-eluting polymer stent system. Catheter Cardiovasc Interv. 2005; 66: 491–5
   Google Scholar
• Kipshidze NN, Iversen P, Kim HS, Yiazdi H, Dangas G, Seaborn R, et al. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter Cardiovasc Interv. 2004; 61: 518–27
   PubMed Web of Science ®Google Scholar
• Kwok OH, Chow WH, Law TC, Chiu A, Ng W, Lam WF, et al. First human experience with angiopeptin-eluting stent: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Catheter Cardiovasc Interv. 2005; 66: 541–6
   PubMed Web of Science ®Google Scholar
• Camici GG, Steffel J, Akhmedov A, Schafer N, Baldinger J, Schulz U, et al. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. Circulation. 2006; 114: 1512–21
   PubMed Web of Science ®Google Scholar
• Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000; 102: 399–404
   PubMed Web of Science ®Google Scholar
• Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008; 371: 899–907
   PubMed Web of Science ®Google Scholar
• Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet. 2007; 369: 1869–75
   PubMed Web of Science ®Google Scholar
• Peuster M, Wohlsein P, Brugmann M, Ehlerding M, Seidler K, Fink C, et al. A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into New Zealand white rabbits. Heart. 2001; 86: 563–9
   PubMed Web of Science ®Google Scholar
• Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006; 113: 722–31
   PubMed Web of Science ®Google Scholar